Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

27.3%

3 terminated/withdrawn out of 11 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

N/A

2(25.0%)

Phase 1

2(25.0%)

8Total

Phase 2(4)

N/A(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT00592865Terminated

Risk Factors for Adult-Onset Brain Tumors

Role: collaborator

NCT00215202Phase 2Completed

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Role: collaborator

NCT00594815Not ApplicableCompleted

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Role: collaborator

NCT00660283Phase 2Unknown

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma

Role: lead

NCT00283556Phase 1Completed

High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

Role: lead

NCT00660621Phase 2Unknown

A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma

Role: lead

NCT00283569Completed

Genetic Epidemiology of Adult Onset Glioma

Role: lead

NCT00283530Terminated

Tumor Phenotypes and Correlation to Clinical Outcomes in Cancer

Role: lead

NCT00264134Phase 1Terminated

Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

Role: lead

NCT00283478Not ApplicableCompleted

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer